Seres Therapeutics (MCRB) Profit After Tax (2014 - 2026)

Seres Therapeutics has reported Profit After Tax for 13 years, with the latest figure at -$19.9 million in Q1 2026.

• Quarterly Profit After Tax fell 160.93% year-over-year to -$19.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46.9 million (down 123.58% YoY) and the FY2025 annual result came in at $5.7 million, up 4088.24% from the prior year.
• Profit After Tax eased to -$19.9 million in Q1 2026 per MCRB's latest filing, from -$15.3 million in the prior quarter.
• Over five years, Profit After Tax peaked at $110.3 million in Q4 2024 and troughed at -$71.2 million in Q1 2023.
• A 5-year average of -$6.8 million and a median of -$19.9 million in 2025 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax sank 39024.53% in 2023, then soared 367.26% in 2024.
• Over 5 years, Profit After Tax stood at $106000.0 in 2022, then tumbled by 39024.53% to -$41.3 million in 2023, then jumped by 367.26% to $110.3 million in 2024, then plunged by 113.91% to -$15.3 million in 2025, then fell by 29.85% to -$19.9 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered -$19.9 million, -$15.3 million, and $8.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.